Modulating immune inhibitory pathways has been a major recent breakthrough in cancer treatment. Checkpoint blockade antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programed cell-death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have demonstrated acceptable toxicity, promising clinical responses, durable disease control, and improved survival in 20-30% of patients with advanced melanoma, and non-small cell lung ...

#Siste magasin


Nr. 1 • desember 2019
1. Årgang
  • Venøs tromboembolisme ved kreft
  • Type 2-diabetes
  • Hepatitt E-virus